Stockreport

KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF KERENDIA® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slop [Read more]